Partnering opportunities

Antigenics seeks to establish corporate partnerships with leading pharmaceutical companies with strengths that complement and enhance our own. Below is more information about current product opportunities for two of our investigational products — Oncophage^® (vitespen; formerly HSPPC-96) patient-specific cancer vaccine and Aroplatin™, a third-generation platinum chemotherapeutic.

Antigenics is also interested in learning more about novel products and technologies that may augment our internal research and development pipeline. Contact Business Development to learn more.

Oncophage

Oncophage is a first-in-class, investigational patient-specific therapeutic cancer vaccine that offers a potentially safer, more effective alternative to conventional anticancer treatments. Currently in Phase 3 trials for kidney cancer and melanoma, Oncophage has been granted US Food and Drug Administration (FDA) fast track designation and orphan drug status in both indications. Oncophage is also in early-stage clinical trials for colorectal, pancreatic and gastric cancers as well as for non-Hodgkin’s lymphoma. Oncophage can potentially be used to treat all cancer types, and can be administered as a monotherapy or in combination with surgery, radiation, chemotherapies or other immunotherapies. The worldwide market opportunity for Oncophage, upon approval, is estimated to be multibillion-dollar.

Compared with other anticancer agents, Oncophage is expected to have three significant advantages:

• Targeted anticancer activity, prolonging life
• Broad applicability, potentially useful in all cancers and multiple stages of disease
• Remarkable safety profile, significantly improving quality of life during treatments

Antigenics plans to establish a US marketing and sales force for Oncophage upon commercialization. The company is currently seeking licensing partners for the commercialization of Oncophage worldwide.

 Learn more about Oncophage or contact Business Development for additional information.

Aroplatin

Aroplatin is an investigational, liposome-encapsulated DACH (diaminocyclohexane) platinum compound currently under development for the treatment of cancer. Its active ingredient is known as NDDP and is a new chemical entity. Aroplatin is currently being tested as a single agent treatment for metastatic colon carcinoma in a Phase 2 clinical trial, as well as for advanced solid tumors in a Phase 1/2 trial. The worldwide market opportunity for Aroplatin, upon approval, is expected to approach $1 billion.

Compared with other platinum agents, Aroplatin is expected to have three significant advantages:

• Improved anticancer activity, even in cisplatin- and carboplatin-resistant cancers
• Reduced toxicity
• Broad applicability, including in traditionally platinum-insensitive cancers (e.g., colon carcinoma)

The current market for platinum agents is more than $900 million per year. Moreover, European sales of oxaliplatin, a structural analogue of Aroplatin, were $171 million in 2001 and are estimated to be more than $250 million in 2002. Oxaliplatin was recently approved in the United States and is projected to have a worldwide market opportunity approaching $1 billion. However, oxaliplatin has the serious limitation of being associated with dose-limiting neurotoxicities. In US registration trials, 74 percent of patients experienced neuropathy, with 48 percent experiencing persistent neuropathy. Aroplatin is expected to demonstrate reduced toxicity and may have the potential to displace oxaliplatin, as well as other platinum agents.

Antigenics is currently seeking licensing partners for the commercialization of Aroplatin worldwide.

 Learn more about Aroplatin or contact Business Development for additional information.

 Find out about existing partnered programs with Antigenics.